Merge Healthcare to Launch New Retinal Screening Solution for Advanced Interoperability, Enhanced Patient Care and Reduced Co...
April 24 2014 - 7:00AM
Merge Healthcare Incorporated (Nasdaq:MRGE), a leading provider of
clinical systems and innovations that seek to transform healthcare,
today announced that it will be releasing iConnect® Retinal
Screening, an, end-to-end retinal screening solution, allowing
providers to quickly identify and diagnose patients with diabetic
retinal disease. Leveraging Merge's cloud infrastructure, iConnect®
Cloud Archive, and Merge Eye Care PACS™, the interoperable,
subscription-based service streamlines operational workflow,
reduces financial costs and enables of the improvement of clinical
care quality.
"Diabetes affects more than 347 million people globally, and
it's estimated that one out of every five U.S. healthcare dollars
is spent on this disease," said Steven Tolle, Chief Strategy
Officer at Merge Healthcare. "By creating a solution that addresses
both patient and provider knowledge gaps, we're helping providers
more easily diagnose and treat not only diabetes, but retinal
disease as a whole. Patients, in turn, are empowered with faster
treatment plans which can reduce the risk of negative side
effects."
The newest offering to be added to the Merge Interoperability
Solution suite, iConnect Retinal Screening enables providers to
efficiently capture retinal images through an automated camera,
reducing the need for staff to receive specialty training. Images
are transferred via the cloud to a reading center where trained
technicians and pathologists bear the responsibility of
identifying, diagnosing and delivering results. The results are
then transmitted electronically, via Merge's iConnect Network, to
the provider's electronic health record (EHR) system to allow for
timely, customized care plans. The first phase of the solution will
offer Diabetic Retinopathy Screening to address the increasingly
common complication of diabetes and one of the leading causes of
visual impairment and blindness among working-aged adults in the
U.S, according to the Centers for Disease Control and
Prevention.
"We saw a clear need in the industry for a solution that solves
a large population health problem especially within accountable
care organizations. By leveraging our existing cloud technology,
Merge customers will be able to enhance care for the large number
of diabetic patients in our nation," added Justin Dearborn, CEO of
Merge Healthcare. "Our deep expertise with other specialty
screenings, such as mammography, cervical and cardiology, positions
us well to help in the eye care market. This new, end-to-end
solution will be a win-win for patients and providers, enabling a
detrimental disease to be diagnosed and treated earlier having the
additional benefit of reducing short- and long-term healthcare
costs."
iConnect Retinal Screening is currently undergoing a pilot
program launch and is scheduled for availability by the end of Q2.
Future stages of the solution will include screenings for glaucoma,
age-related macular degeneration and other serious neurological
disease.
About Merge
Merge is a leading provider of innovative enterprise imaging,
interoperability and clinical systems that seek to advance
healthcare. Merge's enterprise and cloud-based technologies for
image intensive specialties provide access to any image, anywhere,
any time. Merge also provides clinical trials software with
end-to-end study support in a single platform and other intelligent
health data and analytics solutions. With solutions that have been
used by providers for more than 25 years, Merge is helping to
reduce costs, improve efficiencies and enhance the quality of
healthcare worldwide. For more information, visit merge.com and
follow us @MergeHealthcare.
Cautionary Notice Regarding Forward-Looking
Statements
The matters discussed in this news release may include
forward-looking statements, which could involve a number of risks
and uncertainties. When used in this press release, the words
"will," "believes," "intends," "anticipates," "expects" and similar
expressions are intended to identify forward-looking statements.
Actual results could differ materially from those expressed in, or
implied by, such forward-looking statements. Except as expressly
required by the federal securities laws, the Company undertakes no
obligation to update such factors or to publicly announce the
results of any of the forward-looking statements.
CONTACT: Media Contact:
Jennifer Jawor
Vice President, Corporate Marketing
312.565.6825
jennifer.jawor@merge.com
Mirage Energy (PK) (USOTC:MRGE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Mirage Energy (PK) (USOTC:MRGE)
Historical Stock Chart
From Jul 2023 to Jul 2024